Egis Pharmaceuticals Public Limited Company (H-1106 Budapest, Keresztúri út 30-38.,
hereinafter referred to as ’the Company’) informs its distinguished shareholders that, on the
basis of the profit earned during the financial year, which ended September 30, 2012, and
pursuant to the resolution of the Annual General Meeting held on January 30, 2013, a gross
dividend of HUF 240 per share will be paid according to the following rules:
Entitlement to Dividend
Shareholders (individuals, and legal entities or companies without legal personality), are entitled to receive dividend on the conditions that (1) they own Egis share (ISIN: HU0000053947)
on May 14, 2013, which is the record date of the shareholder identification process initiated by
the Company in compliance with the general terms of KELER Zrt. (Central Clearing House
and Treasury Co.), that (2) they are duly entered in the Company’s share ledger with the effect
of May 14, 2013 according to the statements of the identification process described in point
(1), and that (3) all requisites for identification stipulated by Hungarian regulations are presented within the five-year term of limitation to the Company via their securities account keepers.
The Company shall not be obliged to pay dividend beyond five years following the commencing date (May 22, 2013) of the dividend payment, in other words the term of limit is May 22,
2018.